Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma

Virchows Archiv

Volumn 452, Issue 1, 2008, Pages 65-74

  Lerma, Enrique ^a   Romero, Marisa ^a   Gallardo, Alberto ^a   Pons, Cristina ^a   Muñoz, Josefina ^a   Fuentes, Josefina ^a   Lloveras, Belen ^a,b   Catasus, Lluis ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cervix; Fas (CD95 APO 1); Fas ligand; Immunohistochemistry; Single nucleotide polymorphisms; Squamous cell carcinoma

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA SEQUENCE; FEMALE; GENE LOCATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTIGENS, CD95; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA PROBES, HPV; DNA, VIRAL; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 37549001016     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-007-0535-z     Document Type: Article

References (45)

1. Ahlbom A, Lichtenstein P, Malmstrom H, Feychting M, Hemminki K, Pedersen NL (1997) Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst 89:287-293
2. Allen M, Lalantari M, Ylitalo N, Pettersson B, Hagmar B, Scheibenpflug L, Johansson B, Petterson U, Gyllensten U (1996) HLA DQ-DR haplotype and susceptibility to cervical carcinomaL indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 48:32-37
3. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM (1994) HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 6:157-162
4. Boldrini L, Faviana P, Pistolesi F, Gisfredi S, Di Quirico D, Lucchi M, Mussi A, Angeletti CA, Baldinotti F, Fogli A, Simi P, Basolo F, Fontanini G (2001) Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene 20:6632-6637
5. Butler LM, Hewett PJ, Butler WJ, Couled PA (1998) Down-regulation of fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer 77:1454-1459
6. Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R (2000) Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 82:1682-1688
7. Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ (2004) Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 14:475-478
8. Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Med 1:464-470
9. Engelmark MT, Renkema KY, Gyllensten UB (2004) No evidence of the involvement of the Fas-670 promoter polymorphism in cervical cancer in situ. Int J Cancer 112:1084-1085
10. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in human autoimmune lymphoproliferative syndrome. Cell 81:935-946
11. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192
12. Huang QR, Morris D, Manolios N (1997) Identification and characterization of polymorphism's in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34:577-582
13. Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821-822
14. Jones DL, Munger K (1996) Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin Cancer Biol 7:327-337
15. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE (2000) Combined analysis of germline polymorphism's of p53, GSTM1, GSTT1, CYP1A1 and CYP2E1. Relation to the incidence rate of cervical carcinomas. Cancer 88:2082-2091
16. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T, Dillner J (2000) Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82:1332-1338
17. Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, Levine AM, Darragh TM, Weinberg V, Smith-McCune KK (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia. Cancer Res 64:6766-6774
18. Krammer DH (2000) CD95's deadly mission in the immune system. Nature 407:789-795
19. Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, Chu TY (2005) Genetic polymorphism's of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 99:113-118
20. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY (2003) Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103:221-225
21. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY (1999) Alterations of Fas gene in transitional cell carcinomas of urinary bladder. Cancer Res 59:3068-3072
22. Magnusson PK, Sparen P, Gyllensten UB (1999) Genetic link to cervical tumors. Nature 400:29-30
23. Mantovani F, Banks L (2001) The human papilloma virus E6 protein and its contribution to malignant progression. Oncogene 20:7874-7887
24. Matsue H, Kobayashi H, Hosokawa T, Akitaya T, Ohkawara A (1995) Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes. Arch Dermatol Res 287:315-320
25. Milde-Langosch K, Schreiber C, Becker G, Löning T, Stegner HE (1993) Human papillomavirus a detection in cervical adenocarcinomas by polymerase chain reaction. Hum Pathol 24:590-594
26. Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D (1999) Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer 80:564-572
27. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527
28. Nguyen HH, Broker TR, Chow LT, Alvarez RD, Vu HL, Andrasi J, Brewer LR, Jin G, Mestecky J (2005) Immune response to human HPV in genital tract of women with cervical cancer. Ginecol Oncol 96:452-461
29. Nishioka Y, Sagae S, Nishikawa A, Kudo R (2003) A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 200:49-55
30. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
31. Peter ME, Krammer PH (2003) TheCD95(Apo-/Fas) DISC and beyond. Cell Death Differ 10:26-35
32. Pinti M, Troiano L, Nasi M, Moretti L, Monterastelli E, Mazzacani A, Mussi C, Ventura P, Olivieri F, Franceschi C, Salvioli G, Cossarizza A (2002) Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ 9:431-438
33. Ramenghi U, Bonissoni S, Migliaretti G, DeFranco S, Bottarel F, Gambaruto C, DiFranco D, Priori R, Conti F, Dianzani I, Valesini G, Merletti F, Dianzani U (2000) Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune disease and cancer. Blood 95:3176-3182
34. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG (2005) Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96:705-713
35. Sayama K, Yonehara S, Watanabe Y, Miki Y (1994) Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 103:330-334
36. Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC (1999) Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with progression of human cervical carcinoma. Cancer 86:1537-1543
37. Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y (2000) Up-regulation of Fas ligand at early stages and down regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32:761-769
38. Stanczuk GA, Sibanda EN, Perrey C, Chivara M, Pravica V, Hutchinson IV, Tswana SA (2001) Cancer of the uterine cervix may be significantly associated with gene polymorphism's coding for increased IL10 production. Int J Cancer 94:792-794
39. Stanczuk GA, Tswana SA, Bergstrom S, Sibanda EN (2002) Polymorphism's in codons 10 and 25 of TGF gene in patients with invasive squamous cell carcinoma of the uterine cervix. Eur J Immunogenet 29:417-421
40. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2:1361-1366
41. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphism's of death pathway genes FAS in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030-1036
42. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, Noll M, Brocker EB, Blaser K, Akdis CA (2000) T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 106:25-35
43. Ueda M, Hung YC, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M (2005) Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 98:129-133
44. Vidal D, Matias X, Alomar A (2004) Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 29:518-525
45. Waggoner SE (2003) Cervical cancer. Lancet 361:2217-2225